您当前所在的位置:首页 > 产品中心 > 产品信息
Omeprazole_分子结构_CAS_73590-58-6)
点击图片或这里关闭

Omeprazole

产品号 DB00338 公司名称 DrugBank
CAS号 73590-58-6 公司网站 http://www.ualberta.ca/
分子式 C17H19N3O3S 电 话 (780) 492-3111
分子量 345.41606 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 222

产品价格信息

请登录

产品别名

标题
Omeprazole
IUPAC标准名
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
IUPAC传统名
5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-3H-1,3-benzodiazole
商标名
Sanamidol
Exter
Zimor
Ulceral
Belmazol
Ultop
Audazol
Aulcer
Dizprazol
Emeproton
Erbolin
Gastroloc
Gibancer
Losec
Nilsec
Ocid
Peptilcer
Ulcesep
Antra
Danlox
Desec
Epirazole
Inhibitron
Lensor
Mopral
Omegast
Omezol
Omid
Omisec
Ompanyt
Parizac
Pepticum
Regulacid
Ulcometion
Ulcsep
Ulsen
Zefxon
Zegerid
Zepral
Ceprandal
Demeprazol
Dudencer
Elgam
Gasec
Gastrimut
Indurgan
Inhipump
Logastric
Lomac
Mepral
Miol
Miracid
Morecon
Olexin
Omapren
Omebeta 20
Omed
Omeprazon
Omeprol
Omesek
Omezolan
Omizac
Ortanol
Osiren
Ozoken
Paprazol
Pepticus
Prazentol
Prazidec
Prilosec
Procelac
Prysma
Ramezol
Result
Secrepina
Tedec Ulceral
Ulcozol
Ulzol
Victrix
Zoltum
Nopramin
Omepral
Prazolit
Proclor
别名
Omeprazolum [INN-Latin]
OMZ
omeprazole
Omeprazol [INN-Spanish]
OMEP
OMP
Omeprazole magnesium

产品登记号

PubChem CID 4594
PubChem SID 46509065
CAS号 73590-58-6

产品性质

疏水性(logP) 0.6
溶解度 82.3 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; investigational
Description A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and zollinger-ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of gastric parietal cells. [PubChem]
Indication For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Pharmacology Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase at the secretory surface of the gastric parietal cell. As a result, it inhibits acid secretion into the gastric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.
Toxicity Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic.
Absorption Absorption is rapid, absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg.
Half Life 0.5-1 hour
Protein Binding 95%
Elimination Urinary excretion is a primary route of excretion of omeprazole metabolites.
Clearance * total body cl=500-600 mL/min [healthy]
* 250 mL/min [Geriatric]
* 70 mL/min [Hepatic Impairment]
* 10 - 62 mL/min/1.73 m2 [Renal Impairment]
References
Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

  • Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53. Pubmed